Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulotaront in Parkinson's Disease Psychosis
NCT02969369Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing SEP-363856 with Placebo Capsule (2 arms). Primary endpoint: Scale for Assessment of Positive Symptoms - Parkinson's Disease at 6 weeks. Started Dec 2016; status: completed.
02
Drugs
ulotaront
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02969369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969369.